Local Radiotherapy for Residual Tumor Lesions During the First-line Treatment

Efficacy and Safety of Local Radiotherapy for Residual Tumor Lesions During the First-line Treatment of Advanced Non-small Cell Lung Cancer: a Retrospective-real World Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05205226

Enrollment

636

Registered

2022-01-25

Start date

2018-01-02

Completion date

2022-01-02

Last updated

2022-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Small Cell Lung Cancer

Brief summary

This study aimed to confirmed that local radiotherapy for residual lesions can significantly prolong the efficacy of chemotherapy combined with immunotherapy in the initial treatment of advanced non-small cell lung cancer.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* ≥18，Advanced Non-small Cell Lung Cancer Confirmed by Histopathology Patients received platinum-based chemotherapy combined with immunotherapy

Exclusion criteria

* EGFR/ALK/ROS1 driver gene mutation * Chemotherapy only * Concurrent radio-chemotherapy * Surgery * Single-agent immunotherapy * No treatment information available

Design outcomes

Primary

Measure	Time frame	Description
PFS	January 2018 to June 2021	Progression free survival time

Secondary

Measure	Time frame	Description
RT	January 2018 to June 2021	radiotherapy control time

Countries

China

Outcome results